Group 1 - The company is committed to high-quality development and has launched the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, set to be implemented by April 2025 [2][3] - The company focuses on the discovery and optimization of small molecules and nucleic acid drugs, utilizing four core technology platforms: DEL technology, FBDD/SBDD, OBT, and TPD [2][3] - As of mid-2025, the company has synthesized over 1.2 trillion structurally diverse DNA-encoded compounds and holds multiple internal drug projects at various clinical stages [3][4] Group 2 - The DEL segment generated revenue of 102.19 million yuan, a year-on-year increase of 40.45%, driven by flexible and diversified services [4] - The FBDD/SBDD segment reported revenue of 65.24 million yuan, up 4.15%, bolstered by milestone income from the UK subsidiary Vernalis [4] - The company has achieved a net profit of 53.91 million yuan, reflecting a year-on-year growth of 2,517.66% [3][4] Group 3 - The company has obtained 143 invention patents and 14 software copyrights, with over 300 additional patents pending [3][4] - The company was recognized as one of the "Top 20 Excellent CRO Brands in China" for 2025 [3][4] Group 4 - The company emphasizes stable profit distribution, having distributed cash dividends of 23.97 million yuan in June 2025 [5][6] - The controlling shareholder plans to increase their stake in the company by investing between 25 million and 50 million yuan within 12 months [6] Group 5 - The company has expanded its DEL library to over 12 trillion small molecules, making it the largest known library of its kind [7] - The company has developed over 50 novel E3 ligases and constructed over 100 protein constructs for drug discovery [7] Group 6 - The company maintains a strong focus on investor relations, holding a shareholder meeting and utilizing various communication channels to engage with investors [9][10] - The company has implemented a governance structure that includes regular updates to the board and training for directors to enhance operational efficiency [11] Group 7 - The company has established a performance-based compensation system for management, linking bonuses to company performance to align interests with shareholders [12] - The company aims to enhance its core competitiveness through continuous innovation and effective management practices [12]